FLQ Lawsuits Mount as MDL is Considered

As the U.S. Judicial Panel on Multidistrict Litigation gears up to hear oral arguments on a motion to establish a multi-district litigation that would centralize nearly 60 cases against manufacturers of dangerous antibiotics, even more lawsuits continue to be filed. The July 30, 2015 hearing was held on behalf of plaintiffs who allege that makers of antibiotics Avelox, Levaquin, and Cipro caused debilitating, sometimes permanent nerve damage called peripheral neuropathy. Makers of the drugs, including Bayer and Janssen Pharmaceuticals, are being accused of inadequately warning patients and the medical community of the damaging side-effects associated with the potent antibiotics belonging to a class of drugs called fluoroquinolones (“FLQs”). In August 2013, the FDA mandated that a stronger warning be placed on the labels of FLQs including Avelox, Levaquin, and Cipro, but for many, the damage had already been done. Plaintiffs now seek justice from the drugmakers who are alleged to have known about the risky side-effects as early as 2001.

Real Time Analytics